Carregant...
The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses
BACKGROUND: This year marks the twentieth anniversary of the approval by the US Food and Drug Administration of interleukin-2 (IL2) for use in cancer therapy, initially for renal cell carcinoma and later for melanoma. IL2 therapy for cancer has stood the test of time, with continued widespread use i...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3421468/ https://ncbi.nlm.nih.gov/pubmed/22904643 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S33979 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|